<article><a href="https://www.dealstreetasia.com/?s=HiFiBiO%20Therapeutics">HiFiBiO Therapeutics</a>, an emerging multinational biotherapeutics company that seeks to combat diseases by mobilizing the human immune system, has raised $37.5 million in a Series B financing co-led by <a href="https://www.dealstreetasia.com/?s=Sequoia%20China">Sequoia China</a> and <a href="https://www.dealstreetasia.com/?s=LYFE%20Capital">LYFE Capital</a>.</article>

<a href="https://www.dealstreetasia.com/?s=HiFiBiO%20Therapeutics">HiFiBiO Therapeutics</a>, an emerging multinational biotherapeutics company that seeks to combat diseases by mobilizing the human immune system, has raised $37.5 million in a Series B financing co-led by <a href="https://www.dealstreetasia.com/?s=Sequoia%20China">Sequoia China</a> and <a href="https://www.dealstreetasia.com/?s=LYFE%20Capital">LYFE Capital</a>.
Existing Series A investors VI Ventures and Nest.Bio Ventures, as well as new investors Legend Star Capital and Proxima Ventures, also backed the funding round of the US-based startup that also has offices in France and China.
HiFiBiO Therapeutics operates a drug discovery platform, CelliGO, which seeks to develop therapeutic antibodies and immune system modulators through single-B-cell screening, phenotyping, and analysis.
“The platform combines high throughput, single cell, functional-based screening of entire B cell populations with barcoded next-generation sequencing and rapid DNA synthesis to deeply mine tens of millions of B cells in a typical immune response for rare antibody drugs,” the company said.
HiFiBio Therapeutics President and CEO Liang Schweizer said the fresh investments will help expand the company’s drug development team and new facilities on three continents.
The company has entered into multiple antibody discovery collaborations with leading pharmaceutical companies. It currently has more than 50 full-time employees operating out of three facilities in the USA, France, and China.
Both the laboratories in Cambridge, Mass. and Hangzhou, China are located within the Nest.Bio Ventures incubator facilities.
Lynn Yang, Managing Director of Sequoia China, cited HiFiBiO’s combination of deep-rooted biological expertise and truly disruptive single-B-cell cloning technology as compelling factors for Sequoia’s investment.
“This combination could more effectively bring new solutions to fight and ultimately, cure devastating diseases,” Yang said.
Also Read:
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/gic-china-cstone-97520/">Singapore’s GIC leads $260m Series B round in Chinese biopharma firm CStone</a>
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/us-based-stealth-biotherapeutics-eyes-hong-kong-ipo-this-year-97608/">US-based Stealth BioTherapeutics eyes Hong Kong IPO this year</a>

Biotherapeutics company HiFiBiO Therapeutics has raised $37.5 million in a Series B financing co-led by Sequoia China and LYFE Capital.

Sequoia China co-leads $37.5m Series B for biotherapeutics firm HiFiBiO

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Sequoia China co-leads $37.5m Series B for biotherapeutics firm HiFiBiO

Start your deal-making journey now!

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief